BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21564292)

  • 1. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
    Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
    J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
    Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC
    Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on satraplatin: the first orally available platinum anticancer drug.
    Kelland LR
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
    Marcus L; Murphy R; Fox E; McCully C; Cruz R; Warren KE; Meyer T; McNiff E; Balis FM; Widemann BC
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):247-52. PubMed ID: 21706317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Satraplatin: an orally available platinum analog for the treatment of cancer.
    Choy H
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
    Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.
    Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A
    J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid biotransformation of satraplatin by human red blood cells in vitro.
    Carr JL; Tingle MD; McKeage MJ
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):9-15. PubMed ID: 12111106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and future prospects for satraplatin, an oral platinum analogue.
    Choy H; Park C; Yao M
    Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors.
    Rassnick KM; Muindi JR; Johnson CS; Balkman CE; Ramnath N; Yu WD; Engler KL; Page RL; Trump DL
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):881-91. PubMed ID: 18246349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
    Gallerani E; Bauer J; Hess D; Boehm S; Droege C; Jeckelmann S; Miani M; Herrmann R; Marsoni S; Sperka S; Sessa C
    Acta Oncol; 2011 Oct; 50(7):1105-10. PubMed ID: 21184645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
    Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
    J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
    Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.